Claims for Patent: 10,065,952

Summary for Patent: 10,065,952

Title:	Valbenazine salts and polymorphs thereof
Abstract:	Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[- 2,1-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of neurological disorders and diseases including hyperkinetic movement disorders or diseases.
Inventor(s):	McGee; Kevin (San Diego, CA), Zook; Scott (San Diego, CA), Carr; Andrew (Cambridge, GB), Bonnaud; Thierry (Cambridge, GB)
Assignee:	Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:	15/338,214
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,065,952
Patent Claims:	1. A crystal form of the compound of Formula I: ##STR00006## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of: a) 6.3, 17.9, and 19.7.degree..+-.0.2.degree.; or of: b) 6.3, 18.3, and 19.8.degree..+-.0.2.degree.. 2. A crystal form of the compound of Formula I: ##STR00007## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of 5.7, 15.3, and 22.5.degree..+-.0.2.degree.. 3. A crystal form of the compound of Formula I: ##STR00008## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of 6.2, 10.4, and 20.2.degree..+-.0.2.degree.. 4. A crystal form of the compound of Formula I: ##STR00009## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of 6.7, 7.9, and 23.7.degree..+-.0.2.degree.. 5. A crystal form of the compound of Formula I: ##STR00010## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of 6.8, 5.4 and 8.0.degree..+-.0.2.degree.. 6. Amorphous: ##STR00011## having an X-Ray diffraction pattern substantially as shown in FIG. 19. 7. A crystal form of the compound of Formula II: ##STR00012## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of 7.2, 9.2, and 18.0.degree..+-.0.2.degree.. 8. A crystal form of the compound of Formula II: ##STR00013## having an XRPD pattern comprising X-Ray diffraction peaks at two-theta angles of 4.8, 13.3, and 24.9.degree..+-.0.2.degree.. 9. Amorphous: ##STR00014## having an X-Ray diffraction pattern substantially as shown in FIG. 26. 10. A pharmaceutical composition comprising the crystal form of claim 1 and a pharmaceutically acceptable carrier. 11. The pharmaceutical composition of claim 10, wherein the composition is formulated for oral administration. 12. The pharmaceutical composition of claim 10, wherein the composition is formulated as a single dosage form. 13. A method of ameliorating one or more symptoms of a hyperkinetic disorder, comprising administering the crystal form of claim 1. 14. The method according to claim 13, wherein the hyperkinetic disorder is Huntington's disease, tardive dyskinesia, Tourette's syndrome, dystonia, hemiballismus, chorea, or tics. 15. The method according to claim 14, wherein the hyperkinetic disorder is tardive dyskinesia. 16. The method according to claim 14, wherein the hyperkinetic disorder is Tourette's syndrome. 17. A method for inhibiting vesicular monoamine transporter isoform 2 in a subject comprising administering to the subject the crystal form of claim 1.